Ultimately, YOD patients showed an increased risk of developing CKD when the level of fasting glucose, insulin use, and the number of oral hypoglycemic agents, were additionally adjusted for in Model 4 (OR 1.70, 95% CI 1.15–2.51). This evidence concerns the gene INS and chronic kidney disease.